Anti-EIF2A / Eukaryotic translation initiation factor 2A

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. EIF2A antibody detects Eukaryotic translation initiation factor 2A, a noncanonical initiation factor that facilitates translation initiation at non-AUG codons and reinitiation after upstream open reading frames. The UniProt recommended name is Eukaryotic translation initiation factor 2A (EIF2A). This factor functions independently of EIF2 and promotes initiation under stress or viral infection conditions when canonical EIF2-dependent translation is inhibited.Functionally, EIF2A antibody recognizes a 585-amino-acid cytoplasmic protein that mediates the recruitment of initiator Met-tRNA to the ribosome in an EIF2-independent manner. EIF2A interacts with EIF3, ribosomal subunits, and tRNA to enable translation initiation, particularly for internal ribosome entry site (IRES)-containing mRNAs or stress-induced transcripts. Its activity contrasts with EIF2S1 (EIF2-alpha), which forms the classic EIF2 complex with GTP and initiator tRNA.The EIF2A gene is located on chromosome 3q26.2 and is ubiquitously expressed, with high levels in pancreas, liver, and testis. During cellular stress, EIF2A supports translation of mRNAs involved in survival and recovery, including those that escape EIF2-alpha phosphorylation-mediated repression. It also contributes to viral mRNA translation, highlighting its role in host-pathogen interactions.Pathologically, altered EIF2A function has been linked to metabolic disorders, neurodegenerative diseases, and cancer. Its role in selective translation during stress responses connects it to the unfolded protein response and integrated stress response pathways. Research with EIF2A antibody enables detection of translational shifts and analysis of noncanonical initiation mechanisms.EIF2A antibody is suitable for western blot, immunocytochemistry, and immunoprecipitation to detect EIF2A in cultured cells and tissues. It is commonly used in studies of translational control, stress granule dynamics, and viral infection models. NSJ Bioreagents provides EIF2A antibody reagents validated for research in protein synthesis and stress response regulation.Structurally, EIF2A is composed of N-terminal domains that interact with tRNA and ribosomal proteins, and C-terminal extensions involved in EIF3 binding. It differs mechanistically from EIF2S1 in GTP usage and codon selection. This antibody helps delineate EIF2A's contribution to alternative initiation and translational adaptation under stress conditions.